Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors

Hepatology

Volumn 53, Issue 3, 2011, Pages 865-874

  Yang, Hui ^a,b   Zhan, Qi ^a   Wan, Yu Jui Yvonne ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTIOXIDANT; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DEATH; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ANTIOXIDANTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FENRETINIDE; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYDROXYLAMINES; LIVER NEOPLASMS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; QUINOLINES; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; RNA, MESSENGER;

EID: 79952238283     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24101     Document Type: Article

References (39)

1. Hail N Jr, Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006; 11: 1677-1694.
2. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006; 12: 3109-3114.
3. Qian J, Zhang JS, Wang XQ, Ji JL, Mei S. Fenretinide stimulates the apoptosis of hepatic stellate cells and ameliorates hepatic fibrosis in mice. Hepatol Res 2009; 39: 1229-1247.
4. Preitner F, Mody N, Graham TE, Peroni OD, Kahn BB. Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am J Physiol Endocrinol Metab 2009; 297: E1420-E1429.
5. Sogno I, Vene R, Ferrari N, De Censi A, Imperatori A, Noonan DM, et al. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol 2010; 75: 2-14.
6. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008; 7: 740-748.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
8. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
9. Smith KT, Workman JL. Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 2009; 41: 21-25.
10. Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 2006; 6: 369-375.
11. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7-17.
12. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15: 3970-3977.
13. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007; 6: 2976-2984.
14. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001; 61: 3591-3594.
15. Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 2000; 60: 3137-3142.
16. Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010; 235: 32-39.
17. Yang H, Bushue N, Bu P, Yvonne Wan YJ. Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells. Biochem Pharmacol 2010; 79: 948-954.
18. Tan KP, Kosuge K, Yang M, Ito S. NRF2 as a determinant of cellular resistance in retinoic acid cytotoxicity. Free Radic Biol Med 2008; 45: 1663-1673.
19. Bu P, Wan YJ. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer 2007; 7: 236.
20. Zhang XK. Targeting Nur77 translocation. Expert Opin Ther Targets 2007; 11: 69-79.
21. Houle B, Leduc F, Bradley WE. Implication of RARB in epidermoid (squamous) lung cancer. Genes Chromosomes Cancer 1991; 3: 358-366.
22. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, et al. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 1059-1066.
23. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54: 3580-3587.
24. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997; 57: 4158-4161.
25. Li C, Wan YJ. Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett 1998; 124: 205-211.
26. De los Santos M, Zambrano A, Sanchez-Pacheco A, Aranda A. Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol Endocrinol 2007; 21: 2416-2426.
27. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 2004; 10: 1733-1742.
28. Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulie A, Toubert ME, et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007; 26: 4018-4024.
29. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007; 6: 70-81.
30. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009; 285: 210-217.
31. Epping MT, Meijer LA, Bos JL, Bernards R. UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res 2009; 7: 1861-1870.
32. Moll UM, Marchenko N, Zhang XK. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 2006; 25: 4725-4743.
33. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000; 289: 1159-1164.
34. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-540.
35. Yeo MG, Yoo YG, Choi HS, Pak YK, Lee MO. Negative cross-talk between Nur77 and small heterodimer partner and its role in apoptotic cell death of hepatoma cells. Mol Endocrinol 2005; 19: 950-963.
36. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010; 62: 1285-1298.
37. Liu X, Chen X, Zachar V, Chang C, Ebbesen P. Transcriptional activation of human TR3/nur77 gene expression by human T-lymphotropic virus type I Tax protein through two AP-1-like elements. J Gen Virol 1999; 80(Pt 12): 3073-3081.
38. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5: 415-418.
39. Kadara H, Tahara E, Kim HJ, Lotan D, Myers J, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 2008; 68: 4416-4423.